By Curt Pesman and Mary Miller
In an unusual move, sanofi pharmaceutical company has instituted a 50 percent discount, effective immediately, on its latest cancer drug Zaltrap. The reason for the sharp price drop, company officials said, was “market resistance” to the initial price.
One possible result of the price cut is that the new drug may become more widely available. However, due to complex pricing and regulation issues, it’s not yet known how the actual cost to patients will change over the next several months. Fight Colorectal Cancer is gathering more information today on this issue from oncologists and company officials. Read the rest of this entry »